CONBA(SH:600572)2022-10-25 16:00Financial Performance - The company's revenue for Q3 2022 was CNY 1.41 billion, a decrease of 12.37% compared to CNY 1.50 billion in Q3 2021[10] - Net profit attributable to shareholders was CNY 229.33 million, an increase of 4.49% year-on-year[14] - The net profit excluding non-recurring gains and losses was CNY 442.76 million, reflecting a growth of 19.11% compared to the previous year[14] - The company achieved cumulative sales of CNY 2.78 billion from its major brand project, a comparable growth of 10.91% year-on-year[12] - Total operating revenue for the first three quarters of 2022 was CNY 4,488,268,722.41, a decrease of 8.7% compared to CNY 4,914,997,058.37 in the same period of 2021[39] - Net profit for the first three quarters of 2022 was CNY 303,709,538.35, slightly down from CNY 304,066,952.85 in the same period of 2021[42] - The company's total assets amounted to CNY 10,639,427,049.63, a decrease from CNY 11,270,591,634.96 year-over-year[38] - The total comprehensive income attributable to the parent company was CNY 229,775,577.82, an increase from CNY 219,472,755.27 in the previous period, reflecting a growth of approximately 5.93%[45] Sales and Revenue Breakdown - The self-care product business generated sales of CNY 1.88 billion, a decline of 20.66%, but a comparable growth of 10.80% when excluding a subsidiary[11] - Prescription drug sales reached CNY 1.54 billion, a decrease of 4.14%, but a comparable growth of 6.45% when excluding the subsidiary[11] - The market for non-prescription drugs saw a sales increase of 6.91%, with specific products achieving significant growth[11] Cash Flow and Liquidity - The company experienced a decline in cash flow from operating activities, with a net cash flow of CNY 519.27 million for the year-to-date[6] - The company's cash and cash equivalents decreased to RMB 1,891,846,299.35 from RMB 2,573,269,180.24, representing a decline of 26.5%[33] - The net cash flow from operating activities was CNY 519,268,865.96, slightly down from CNY 554,260,329.67 in the previous year, indicating a decrease of about 6.31%[49] - The cash received from sales of goods and services was CNY 4,066,906,508.23, compared to CNY 4,576,697,810.82 in the same period last year, representing a decline of approximately 11.14%[46] - The ending cash and cash equivalents balance was 1,458,812,866.73, significantly higher than 199,795,348.63 from the previous period, showing improved liquidity[64] Investments and Acquisitions - The company completed the acquisition of 100% equity in Otto Kang Technology Company for RMB 35.58 million, making it a wholly-owned subsidiary[29] - The company also acquired 51% equity in Zhejiang University of Traditional Chinese Medicine's herbal medicine company for RMB 169.83 million, increasing its stake to 66%[29] - Investment income increased by 75.47%, as the company began recognizing investment income from its 38% stake in Zhenzhiming Company starting January 2022[17] - The company reported an investment income of CNY 265,554,181.02, down from CNY 564,431,823.85 in the same period of 2021[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 109,638[21] - The largest shareholder, Zhejiang Traditional Chinese Medicine Health Industry Group, holds 20.85% of the shares, totaling 535,777,040 shares[21] Financial Position - Total liabilities were CNY 3,443,246,793.68, down from CNY 3,640,512,881.62 in the previous year[38] - The company's total equity decreased to CNY 6,370,303,144.22 from CNY 6,595,073,223.53 in the previous year[57] - The company's long-term equity investments slightly decreased to RMB 1,461,887,175.88 from RMB 1,469,429,110.45[33] Future Plans and Strategies - The company plans to expand its online retail business and enhance its product structure to improve market coverage[9] - The company has proposed a stock option incentive plan to grant 70 million stock options to key personnel to align interests[26] - The company plans to issue up to RMB 10 billion in short-term financing bonds and medium-term notes to optimize its debt structure[29] - The company has plans for market expansion and new product development, although specific details were not provided in the content[63]